BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...advance preclinical development of its COVID-19 vaccines. The company also added CEO Anna Sumeray and ex-TVM Capital...
BioCentury | Oct 15, 2018
Company News

New CEO Forster eyes capital raise for F-star

...IPO. In 2011, F-star raised $45.9 million in a series A round from Atlas Venture, TVM Capital...
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

...deal is expected to close in 3Q18. Lilly discovered the compound but sold it to TVM Capital...
BioCentury | May 18, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

...solid tumors. Lilly, which discovered the compound and completed preclinical toxicology studies, sold it to TVM Capital...
BioCentury | May 14, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

...solid tumors. Lilly, which discovered the compound and completed preclinical toxicology studies, sold it to TVM Capital...
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

...syndrome, a collagen production disorder. Concurrently with the merger, a syndicate led by existing shareholder TVM Capital...
BioCentury | Jul 7, 2017
Financial News

Genetic disease testing company Centogene raises €25M series A

...AG (Rostock, Germany) raised €25 million ($28 million) in a series A round led by TVM Capital...
BioCentury | Jul 6, 2017
Financial News

Acer plans to raise $15.7M ahead of Opexa merger

...it will raise $15.7 million from a syndicate of new and existing shareholders led by TVM Capital...
BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

...syndrome, a collagen production disorder. Concurrently with the merger, a syndicate led by existing shareholder TVM Capital...
BioCentury | Dec 16, 2016
Financial News

AL-S Pharma completes venture round

...AL-S Pharma raised an undisclosed amount in a venture round from Neurimmune Holding AG and TVM Capital...
Items per page:
1 - 10 of 183
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...advance preclinical development of its COVID-19 vaccines. The company also added CEO Anna Sumeray and ex-TVM Capital...
BioCentury | Oct 15, 2018
Company News

New CEO Forster eyes capital raise for F-star

...IPO. In 2011, F-star raised $45.9 million in a series A round from Atlas Venture, TVM Capital...
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

...deal is expected to close in 3Q18. Lilly discovered the compound but sold it to TVM Capital...
BioCentury | May 18, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

...solid tumors. Lilly, which discovered the compound and completed preclinical toxicology studies, sold it to TVM Capital...
BioCentury | May 14, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

...solid tumors. Lilly, which discovered the compound and completed preclinical toxicology studies, sold it to TVM Capital...
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

...syndrome, a collagen production disorder. Concurrently with the merger, a syndicate led by existing shareholder TVM Capital...
BioCentury | Jul 7, 2017
Financial News

Genetic disease testing company Centogene raises €25M series A

...AG (Rostock, Germany) raised €25 million ($28 million) in a series A round led by TVM Capital...
BioCentury | Jul 6, 2017
Financial News

Acer plans to raise $15.7M ahead of Opexa merger

...it will raise $15.7 million from a syndicate of new and existing shareholders led by TVM Capital...
BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

...syndrome, a collagen production disorder. Concurrently with the merger, a syndicate led by existing shareholder TVM Capital...
BioCentury | Dec 16, 2016
Financial News

AL-S Pharma completes venture round

...AL-S Pharma raised an undisclosed amount in a venture round from Neurimmune Holding AG and TVM Capital...
Items per page:
1 - 10 of 183